NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-04 18:18இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Aether Industries Releases Q2 FY27 Earnings Call Transcript: CRAMS & CEM Over 65% of Sales
Aether Industries has submitted the transcript of its Q2 FY27 earnings conference call held on October 30, 2026. Management highlighted that CRAMS and CEM segments together now contribute over 65% of total sales, supported by expanding partnerships with Baker Hughes and Dow Silicones. Commercial shipments have commenced to semiconductor customers, with management targeting 300 to 400 tons of sales by FY29 at realization rates of USD 45 to USD 50 per kg. Working capital expanded as inventory days rose to 172 days from 151 days in March (an increase of about ₹180 crore in inventory over 6 months), driven by raw material buffer stocks for new sites.
உச்சம் நம்பிக்கை
என்ன மாறியதுAether released its detailed Q2 FY27 conference call transcript outlining operational milestones across Baker Hughes, Dow, and new semiconductor product lines.
ஏன் இது முக்கியம்Provides forward-looking visibility into capacity commercialization at the Magnum site and growth vectors in high-margin semiconductor and CRAMS verticals, alongside working capital metrics.
CRAMS & CEM share of sales: >65%Oil & gas share of sales: 33%Targeted semiconductor volume (by FY29): 300 to 400 tonsSemiconductor realization range: USD 45 to USD 50 a kiloInventory days: 172 days (vs 151 days in March)Six-month inventory addition: INR 180 கோடி
📅 குறுகிய காலம்Neutral; the transcript details operational commentary already known post-results, though elevated inventory days (172 days) could remain a working capital talking point.
📈 நீண்ட காலம்Strong structural pipeline as business mix pivots toward contract manufacturing (>65% sales) and semiconductor chemicals, supporting long-term margins if execution timelines are met.
⚠ அபாய எச்சரிக்கைகள்
Working capital stretch with inventory days rising to 172 days
Supply chain dependency on Far East raw materials
👀 கவனிக்க வேண்டியவை
Track the commercialization timeline of the Magnum site semiconductor block in Q4 FY27 and monitor whether inventory days normalize in upcoming quarters.
Aether Industries shared Q2/H1 FY27 performance updates via an FAQ presentation, reporting sales growth of 23.96% YoY and 6.33% QoQ driven by CEM (+50.03% YoY) and CRAMS (+23.91% YoY). Combined CEM and CRAMS revenue mix reached 65.97%, approaching the company's long-term 70% target. EBITDA margin for H1 FY27 expanded by 88 bps YoY to 31.64%, despite logistics cost pressures. The company guided full-year FY27 capex at ₹300-350 Cr (approx. 25-29% of TTM revenue), with new production blocks at Site Magnum targeting commercialization by Q3/Q4 FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுAether released operational and financial FAQ disclosures detailing H1 FY27 margin expansion, vertical-level performance, and capacity utilization across sites.
ஏன் இது முக்கியம்Demonstrates structural margin resilience (31.64%) and revenue shift toward high-margin CEM/CRAMS segments, alongside substantial ongoing capex equal to ~25-29% of TTM revenue.
Q2 YoY Sales Growth: 23.96%H1 FY27 EBITDA Margin: 31.64%Planned FY27 Capex: ₹3,000 million ~ ₹3,500 millionPlanned Capex vs TTM Revenue: ~24.5% - 28.6%Total Debt (Sep 30, 2026): ₹6,237 million
📅 குறுகிய காலம்Market sentiment should be supported by strong volume ramp-up in CEM and commercial sales initiation of semiconductor materials from October 2026.
📈 நீண்ட காலம்Commissioning of the Magnum site blocks and the new R&D centre by Q2 FY28 supports targeted ~35% long-term revenue CAGR and product diversification into semiconductors and material science.
⚠ அபாய எச்சரிக்கைகள்
Net working capital stretched to 165 days (inventory days rose to 172 days)
Significant outstanding borrowings of ₹623.7 Cr vs net worth of ₹2,410 Cr
👀 கவனிக்க வேண்டியவை
Track the commercialization timeline of the semiconductor and agrochemical blocks at Site Magnum in Q3-Q4 FY27, as well as the working capital normalization.
Aether Q2 FY27 PAT Rises 26% YoY to ₹68 Cr; Revenue Up 24% to ₹347.2 Cr
Aether Industries reported a 24% YoY growth in Q2 FY27 consolidated revenue from operations to ₹347.2 Cr (₹3,472 M) compared to ₹280.1 Cr in Q2 FY26. Consolidated EBITDA increased by 29% YoY to ₹110.4 Cr with an EBITDA margin of 31.8%, while PAT expanded 26% YoY to ₹68.0 Cr. Revenue contribution from Contract/Exclusive Manufacturing (CEM) and CRAMS stood at 66%, driven by strong momentum in the Oil & Gas (33.4%) and Pharmaceuticals (26.6%) segments. Site 3++ commercial production started and Site 5 Phase One began commercial operations in Q1 FY27, with additional blocks expected in Q4 FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுAether released its Q2/H1 FY27 investor presentation highlighting 24% revenue growth, operationalization of Site 3++, and progress on Site 5 capacity additions.
ஏன் இது முக்கியம்Demonstrates successful strategic pivoting toward higher-margin CEM and CRAMS models (now 66% of revenue) and expands long-term manufacturing infrastructure across agrochemical and semiconductor lines.
📅 குறுகிய காலம்Operating margins remaining robust at ~31.8% and steady execution in Oil & Gas and Material Science should provide near-term earnings support.
📈 நீண்ட காலம்Scaling up Site 5 (visibility for 14 production blocks) and R&D infrastructure enhances CRAMS/CEM capability, supporting management's target of achieving 70% revenue share from contract manufacturing.
⚠ அபாய எச்சரிக்கைகள்
High client and sector dependency on Oil & Gas (33.4%) and Pharmaceuticals (26.6%)
Execution and ramp-up risks at newly commissioned sites (Site 3++ and Site 5)
👀 கவனிக்க வேண்டியவை
Track the ramp-up at Site 3++ and commercial commissioning of two additional production blocks at Site 5 (scheduled for Q4 FY27), along with progress on the new R&D building targeted for Q1 FY28.
Crisil Upgrades Aether Industries' Long-Term Rating to AA-/Stable on ₹636 Cr Facilities
Crisil Ratings has assigned credit ratings to Aether Industries' bank loan facilities totaling ₹636.00 crore. The long-term rating has been assigned at 'Crisil AA-/Stable' compared to its previous rating of 'ICRA A+ (Stable)', reflecting an upgrade in credit profile. The short-term rating was assigned at 'Crisil A1+' against 'ICRA A1' previously. The rated facilities include ₹396 crore in cash credit, ₹150 crore in term loans, and ₹88 crore in proposed limits.
உச்சம் நம்பிக்கை
என்ன மாறியதுAether appointed Crisil Ratings, which assigned a higher rating profile (AA-/Stable and A1+) on ₹636 crore bank facilities compared to previous ICRA ratings (A+/Stable and A1).
ஏன் இது முக்கியம்A credit rating upgrade to AA- enhances the company's financial flexibility and can reduce interest costs on working capital and term debt, supporting return ratios.
Total bank facilities rated: Rs. 636.00 crRated facilities vs TTM revenue: ~55.1%Term loan component: Rs. 150 crCash credit limits: Rs. 396 cr
📅 குறுகிய காலம்Positive sentiment impact as the rating upgrade confirms improving balance-sheet health and banking relationships.
📈 நீண்ட காலம்Enhances access to lower-cost credit to fund ongoing capex (Sites 3, 4, and 5) while maintaining a conservative debt-to-equity ratio (currently at 0.15).
⚠ அபாய எச்சரிக்கைகள்
Proposed limits of ₹88 crore must be availed within 180 days or require revalidation
High exposure to chemical cycle and raw material price volatility
👀 கவனிக்க வேண்டியவை
Track whether the improved credit rating translates into lower borrowing costs on existing and incremental debt, and monitor the utilization of the ₹88 crore proposed fund-based limits.
₹2,300 Cr Capex for Site 5 and Strategic Dow Partnership for Silicones
Aether Industries is executing a massive expansion strategy, headlined by a ₹2,200-₹2,300 Cr investment in its 'Magnum' Site 5, which represents nearly 200% of its TTM revenue. The company is pivoting its revenue mix toward high-margin Contract Exclusive Manufacturing (CEM) and CRAMS, targeting a 70%+ share within two years. A landmark multi-year research partnership with Dow Chemical has been launched to develop silicone manufacturing technologies, marking Aether's entry into a new platform chemistry. Additionally, the company is positioning itself as an upstream supplier for the AI and 5G semiconductor markets through advanced low-dielectric materials.
உச்சம் நம்பிக்கை
என்ன மாறியதுAether has transitioned from a specialty chemical manufacturer to a strategic R&D and manufacturing partner for global giants like Dow and Baker Hughes, while entering the semiconductor material supply chain.
ஏன் இது முக்கியம்The scale of the ₹2,300 Cr capex relative to the company's current ₹1,153 Cr TTM revenue indicates a massive capacity leap that could significantly re-rate the business if the targeted 1.5-1.75x asset turns are achieved.
Site 5 Total Investment: ₹2,300 கோடிCapex vs TTM Revenue: 199.4%CEM EBITDA Margin: 28-30%Expected Asset Turn (Site 5): 1.5 to 1.75Target CEM/CRAMS Revenue Mix: 70%+
📅 குறுகிய காலம்Positive sentiment expected following the Dow partnership announcement and clear visibility on Site 5 Phase 1 ramp-up.
📈 நீண்ட காலம்Structural transformation into a high-end material science company for AI, 5G, and Silicones could sustain high growth for several years.
⚠ அபாய எச்சரிக்கைகள்
Execution risk on large-scale ₹2,300 Cr capex
High valuation (P/E 95.7)
Dependency on global tech cycles for AI/5G materials
👀 கவனிக்க வேண்டியவை
Watch for the execution timeline of Site 5 Phase 2 (FY2030) and the commercialization of the Dow silicone partnership, as these are critical for justifying the current high P/E valuation.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Aether Q1 FY27 PAT at ₹48.4 Cr; Promoters Re-appointed for 5-Year Terms
Aether Industries reported a standalone total comprehensive income of ₹48.38 Cr for Q1 FY27, representing a 20.1% growth compared to ₹40.26 Cr in the same quarter last year. The Board approved the re-appointment of the founding promoter family, including MD Ashwin Desai, for new 5-year terms starting October 2026, ensuring leadership continuity. The company also received a final insurance settlement of ₹26.01 Cr related to a 2023 fire incident. While YoY performance improved, the quarterly EPS of ₹3.64 is slightly lower than the ₹4.07 reported in the immediate preceding quarter (Mar 2026).
உச்சம் நம்பிக்கை
என்ன மாறியதுReported Q1 FY27 financial results and secured management continuity for the next five years through promoter re-appointments.
ஏன் இது முக்கியம்The earnings growth confirms the company's trajectory in specialty chemicals, while leadership stability is critical for executing its massive 172% R&D capacity expansion plan.
Q1 FY27 PAT (Comprehensive): ₹48.38 கோடிYoY PAT Growth: 20.1%Insurance Settlement Received: ₹26.01 கோடிQ1 FY27 EPS: ₹3.64Settlement vs TTM Revenue: ~2.25%
📅 குறுகிய காலம்The stock may see positive sentiment due to YoY earnings growth and the resolution of a major historical insurance claim.
📈 நீண்ட காலம்Leadership continuity for 5 years supports the long-term strategy of shifting revenue mix toward high-margin CRAMS and CEM services.
⚠ அபாய எச்சரிக்கைகள்
High management concentration within the promoter family
Pending insurance claim for ₹7 Cr inventory loss from March 2026 fire
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery of the ₹7 Cr insurance claim for the March 2026 warehouse fire and the commissioning timelines for Site-3, 4, and 5 expansions to sustain the 35% growth target.
Aether Partners with Dow India for Silicone Tech; R&D Capacity Expanding 172%
Aether Industries has announced a collaborative research program with Dow Chemical International to develop silicone manufacturing technologies in India. The research and pilot-scale development will be conducted at Aether's Surat facilities, leveraging their ongoing R&D expansion from 55 to 150 fume hoods (a 172% increase). While the immediate contract value is not disclosed, the agreement includes a framework for long-term strategic partnership and potential industrial-scale manufacturing. This collaboration aligns with Aether's goal to increase its CEM and CRAMS revenue mix to 70-75%.
உச்சம் நம்பிக்கை
என்ன மாறியதுAether has secured a strategic R&D partnership with global major Dow Chemical, specifically targeting the silicone materials market.
ஏன் இது முக்கியம்This validates Aether's technical capabilities in complex chemistry and strengthens its CRAMS pipeline, which is central to its 35% CAGR growth strategy and margin expansion goals.
📅 குறுகிய காலம்The announcement is likely to be viewed positively by the market as it validates Aether's R&D-led business model through a partnership with a global industry leader.
📈 நீண்ட காலம்If successful, this collaboration could lead to significant long-term manufacturing contracts in the silicone space, supporting the company's structural shift toward higher-margin specialty chemicals.
👀 கவனிக்க வேண்டியவை
Watch for the transition of this research program into commercial-scale manufacturing orders, which would provide more visibility on revenue contribution. Monitor the completion timeline of the R&D expansion at the Surat facility.
Aether Q1 FY27 PAT up 33% to Rs 62.7 Cr; Site 5 Phase One Commences Operations
Aether Industries reported a strong Q1 FY27 with revenue rising 27% YoY to Rs 326.6 Cr and PAT increasing 33% to Rs 62.7 Cr. The company successfully operationalized Site 5 Phase One (2 production blocks) and Site 3++, while onboarding 10 new customers. High-margin CEM and CRAMS segments now contribute 60% of revenue, with a target to reach 70% within two years. R&D investment remains robust at 6.16% of revenue (Rs 19.8 Cr) to fuel future product launches.
உச்சம் நம்பிக்கை
என்ன மாறியதுCommercialization of new production blocks at Site 5 and Site 3++, alongside a 10-customer expansion in the client base.
ஏன் இது முக்கியம்Validates the company's strategy to shift towards higher-margin contract manufacturing and research services, reducing reliance on Large Scale Manufacturing (LSM) and supporting its 35% CAGR target.
Q1 FY27 Revenue: Rs 326.6 கோடிQ1 வருவாய் vs TTM வருவாய்: 28.3%Q1 FY27 PAT: Rs 62.7 கோடிCEM/CRAMS Revenue Share: 60%R&D Spend: Rs 19.8 கோடி
📅 குறுகிய காலம்Positive sentiment expected as the company demonstrates strong YoY growth and margin stability at 31% EBITDA despite previous warehouse fire impacts.
📈 நீண்ட காலம்Structural growth is supported by massive R&D expansion (targeting 150 fume hoods) and the operationalization of multiple new sites (3, 4, and 5) to capture global specialty chemical demand.
⚠ அபாய எச்சரிக்கைகள்
Chinese pricing pressure (potential 10-15% revenue impact)
High valuation (P/E 90.1) leaves little room for execution delays
👀 கவனிக்க வேண்டியவை
Monitor the revenue ramp-up from Site 5 Phase One in Q2 FY27 and the construction progress of the new R&D center (Catalyst/Site-1) expected by Q1 FY28.
Aether Industries Commences Commercial Operations at Manufacturing Site 5 Phase 1
Aether Industries has officially started commercial operations at its Manufacturing Site 5 located in GIDC Panoli, Gujarat, as of June 26, 2026. The initial operations cover two blocks within the first phase of this new facility, marking a significant step in the company's growth trajectory. This site is strategically positioned to significantly boost the company's production capacity and drive future revenue growth. Investors should view this as a key milestone in the company's long-term expansion strategy.
முக்கிய அம்சங்கள்
Commercial operations commenced at Manufacturing Site 5 (Plot No. 14+15, GIDC Panoli) on June 26, 2026.The launch includes two specific blocks within the first phase of the site's development.The facility is expected to be a primary driver for achieving extended production capacities.Management anticipates this site will contribute significantly to the company's revenue growth in the coming years.
👀 கவனிக்க வேண்டியவை
This expansion signals strong execution of growth plans; investors should monitor the ramp-up of this facility and its impact on upcoming quarterly revenue figures.
Aether Industries Receives Final Insurance Claim Settlement for 2023 Fire Accident
Aether Industries Limited has received the final insurance claim settlement on June 5, 2026, for the fire accident that occurred on November 29, 2023. The company stated that this final amount successfully offsets all losses reported from the incident. This concludes a long-standing recovery process involving multiple regulatory updates since late 2023.
முக்கிய அம்சங்கள்
Final insurance claim settlement received on the evening of June 5, 2026.Settlement pertains to the fire accident reported on November 29, 2023.The company has successfully managed to offset all losses incurred due to the fire.This marks the conclusion of a series of updates provided between November 2023 and January 2025.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development as it removes the financial uncertainty related to the 2023 fire losses. The full recovery of losses strengthens the balance sheet and concludes a significant legacy issue.
Aether Industries: ICRA Reaffirms [ICRA]A+ Rating; Outlook Revised to Stable from Positive
ICRA has reaffirmed Aether Industries' long-term rating at [ICRA]A+ and short-term rating at [ICRA]A1 for bank facilities totaling Rs. 296 crore. While the ratings remain investment grade, the outlook has been revised from 'Positive' to 'Stable' following the review of FY2026 financial results. The facilities include cash credit and letter of credit limits from ICICI Bank, HDFC Bank, and Axis Bank. This adjustment reflects a stabilization of the credit profile rather than the previously anticipated upward trajectory.
முக்கிய அம்சங்கள்
Long-term rating reaffirmed at [ICRA]A+ for Rs. 296 crore bank facilitiesOutlook revised from Positive to Stable based on FY2026 financial performanceShort-term rating for non-fund-based limits reaffirmed at [ICRA]A1Total rated exposure of Rs. 296 crore distributed across ICICI, HDFC, and Axis BankRating action follows the company's annual financial results released on May 15, 2026
👀 கவனிக்க வேண்டியவை
The revision to a 'Stable' outlook suggests that immediate rating upgrades are unlikely; investors should focus on the company's ability to maintain margins. No immediate action is required as the core investment-grade rating remains intact.
Aether Industries Q4 FY26: Strong 20% YoY Pricing Growth and Site 4 Revenue Jumps 4x
Aether Industries reported a robust Q4 FY26, characterized by a 20% YoY increase in product pricing and a significant 4x revenue surge from Site 4 to INR 220 crores. The company's business mix is shifting towards higher-margin segments, with CRAMS and CEM now contributing 55% of total revenue. Management has provided a positive outlook with the commissioning of Site 5 and Site 3++, aiming for CRAMS/CEM to exceed 70% of sales in the coming years. Additionally, the company is doubling its R&D capacity by FY28 and expanding its global leadership to target the semiconductor and material science sectors.
முக்கிய அம்சங்கள்
Product pricing increased by 20% YoY and 18% QoQ in Q4 FY26, driven by global supply chain disruptions.Site 4 revenue grew from INR 50 crores to INR 220 crores, now representing 21% of total sales.Three new large-scale manufacturing products (2 Pharma, 1 Agro) are set for commissioning by early June 2026 at Site 5.CRAMS and CEM business models contributed 55% of revenue, with 19 new marquee clients added during the year.R&D expansion is on track to double current capacity by Q2 FY28, supporting increased inquiries in material sciences.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful ramp-up of Site 5 and the company's ability to maintain high margins as CRAMS projects transition to exclusive manufacturing. The stock remains a high-growth play in the specialized chemical and R&D services space.
Aether Industries Approves FY26 Results; Reports ₹70M Fire Loss and Appoints Europe BD Head
Aether Industries approved its FY26 financial results, which were impacted by a ₹70 million inventory loss due to a fire at an external warehouse in March 2026. The company's subsidiary, Aether Speciality Chemicals, contributed significantly with a revenue of ₹2,199.72 million and a PAT of ₹496.39 million. To bolster international growth, the board appointed Guenter Stevens, a veteran with 40 years of experience, as the Business Development Leader for Europe. Additionally, the company is still resolving an insurance claim from a 2023 fire, with ₹89.68 million currently recognized as a receivable.
முக்கிய அம்சங்கள்
Recognized a ₹70 million inventory loss in Q4 FY26 results due to a warehouse fire on March 11, 2026.Appointed Guenter Stevens as Business Development Leader – Europe to drive international expansion starting June 2026.Subsidiary Aether Speciality Chemicals reported FY26 revenue of ₹2,199.72 million and PAT of ₹496.39 million.Ongoing insurance claim for a 2023 fire incident shows ₹89.68 million still pending as a receivable after receiving ₹210 million.Consolidated financial results for the year ended March 31, 2026, have been audited and approved by the board.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's safety protocols and insurance recovery progress given the recurring fire incidents. The appointment of a senior leader for Europe is a positive move for long-term growth, but short-term margins may be pressured by the recent inventory loss.
Aether Industries FY26 Revenue Grows 38% to ₹11,601M; PAT Up 39%
Aether Industries reported a strong financial performance for FY26, with consolidated revenue rising 38% to ₹11,601 million and PAT increasing 39% to ₹2,195 million. The growth was largely driven by the Contract Exclusive Manufacturing (CEM) and CRAMS segments, which now contribute over 55% of total revenue. While Q4 FY26 EBITDA was impacted by a ₹70 million inventory loss due to a fire at an external warehouse, overall EBITDA margins for the year improved to 31%. The company is aggressively expanding capacity, with Site 3++ now operational and Site 5 Phase 1 expected to start commercial production in June 2026.
முக்கிய அம்சங்கள்
FY26 Consolidated Revenue grew 38% Y/Y to ₹11,601 million with EBITDA up 53% to ₹3,547 million.Contract Exclusive Manufacturing (CEM) segment revenue share increased to 46.3% in FY26 compared to 34% in FY25.Site 5 Phase 1 commercial production is scheduled for June 2026, with Phase 2 expansion already underway.R&D investment stood at ₹862.13 million in FY26, accounting for 7.3% of total revenues.The company onboarded 19 new customers across all business models during the financial year.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful ramp-up of Site 3++ and the upcoming Site 5, which are critical for sustaining growth in FY27. The increasing revenue share from high-margin CEM and CRAMS segments is a positive indicator of long-term profitability.
Aether Industries Commences Commercial Operations at Manufacturing Site 3++
Aether Industries has officially commenced commercial operations at its new Manufacturing Site 3++ in Surat, Gujarat, effective February 22, 2026. This facility, located at Plot No. 8202/2/A-B, is designed to significantly boost the company's total production capacity. Management expects this site to be a primary contributor to revenue growth in the coming fiscal periods. The timely operationalization of this site demonstrates the company's ability to execute large-scale infrastructure projects.
முக்கிய அம்சங்கள்
Commercial operations at Manufacturing Site 3++ started on February 22, 2026Facility is located at Plot No. 8202/2/A-B in Sachin GIDC, SuratSite is expected to be a key contributor to production capacity and revenue growthExpansion aligns with the company's long-term strategy to scale specialty chemical manufacturing
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive growth catalyst and monitor the facility's utilization levels in upcoming quarterly reports. The expansion supports a long-term growth outlook for the stock as it scales its manufacturing base.
Aether Industries Q3 FY26: PAT Jumps 49% YoY to ₹64.5 Cr; EBITDA Margins Expand to 34%
Aether Industries reported a robust Q3 FY26 with revenue growing 44% YoY to ₹317.1 crore and PAT increasing 49% to ₹64.5 crore. The company achieved significant operational leverage as EBITDA margins expanded to 34% from 28% in the previous year. Strategic diversification is evident as the combined share of Oil & Gas and Material Science rose to 40%, reducing reliance on Pharma and Agro. Management confirmed that Site 3++ and the first two blocks of Site 5 are ready for commercial production, which will drive future volume growth.
முக்கிய அம்சங்கள்
Revenue from operations increased 44% YoY to ₹3,171 million in Q3 FY26.EBITDA surged 75% YoY to ₹1,083 million with margins improving by 600 bps to 34%.Site 4 (Baker Hughes) revenue grew 20% QoQ to ₹60 crore, with further scale-up expected in FY27.Successfully forayed into electronic chemicals for the semiconductor industry with clients in Japan, South Korea, and Taiwan.Volume growth in large-scale manufacturing exceeded 25% YoY, supported by stable pricing.
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook given the strong margin expansion and successful diversification into high-growth sectors like semiconductors and oil & gas. The upcoming commercialization of Site 5 provides a clear catalyst for revenue growth in FY27.
Aether Industries Q3 FY26 PAT Jumps 49% Y/Y to ₹645M; Revenue Up 44%
Aether Industries reported a strong Q3 FY26 with consolidated revenue growing 44% Y/Y to ₹3,171 million, driven by growing CEM contracts and LSM demand. EBITDA rose 75% Y/Y to ₹1,083 million, reflecting significant operating leverage and a shift in segment mix. Net profit (PAT) for the quarter increased 49% Y/Y to ₹645 million, while the 9M FY26 PAT of ₹1,655 million has already exceeded the full-year FY25 figure. The company confirmed that commercial production at Site 5 Phase 1 and Site 3++ is scheduled to begin in March 2026.
முக்கிய அம்சங்கள்
Consolidated Revenue for Q3 FY26 stood at ₹3,171 million, up 44% Y/Y and 13% Q/Q.EBITDA grew 75% Y/Y to ₹1,083 million with a 9M FY26 EBITDA margin of 31.83%.Contract/Exclusive Manufacturing (CEM) contribution increased to 43% of revenue in Q3 FY26 from 38% in Q3 FY25.Site 5 Phase 1 and Site 3++ expansion projects are on track for commercial production by March 2026.R&D spending for 9M FY26 reached ₹606.09 million, accounting for 7.01% of total revenues.
👀 கவனிக்க வேண்டியவை
Investors should note the strong growth in high-margin CEM contracts and the upcoming capacity expansions as key growth catalysts. The fact that 9M FY26 profits have already surpassed full-year FY25 levels indicates a significant earnings breakout.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
